| Year |
Citation |
Score |
| 2020 |
Zhuang E, Jakowatz JG, Yamamoto M, Fruehauf JP. Open label, phase II study of axitinib, a selective inhibitor of vascular endothelial growth factor receptors, in patients with stage III malignant melanoma. Journal of Clinical Oncology. 38: e22062-e22062. DOI: 10.1200/Jco.2020.38.15_Suppl.E22062 |
0.414 |
|
| 2020 |
Fruehauf JP, Gomez DC, Spitalny L, Kim J. Abstract 4098: Topotecan-mediated inhibition of HIF1α/ARV7 heterodimers in 22RV1 prostate cancer cells prevents ARV7 nuclear entry, reversing enzalutamide resistance Cancer Research. 80: 4098-4098. DOI: 10.1158/1538-7445.Am2020-4098 |
0.42 |
|
| 2019 |
Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP. HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular Cancer Research : McR. PMID 31088908 DOI: 10.1158/1541-7786.Mcr-18-1109 |
0.773 |
|
| 2018 |
Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. PMID 29943192 DOI: 10.1007/S00280-018-3624-6 |
0.773 |
|
| 2018 |
Longoria T, Sill M, Monk B, Fruehauf J, Liao S, Emerson R, Kim J, Mannel R, Lee Y, Mathews C, Randall L, Darcy K, Birrer M, Tewari K. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study Gynecologic Oncology. 149: 37-38. DOI: 10.1016/J.Ygyno.2018.04.084 |
0.316 |
|
| 2017 |
Fruehauf JP, Farrokh N, Sarkissian S, Kim J. Abstract A37: Blockade of ARV7:HIF1α; heterodimers after toptoecan reverses enzalutamide resistance in 22Rv1 cells Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-A37 |
0.409 |
|
| 2016 |
Sarkissian S, Fruehauf JP. Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series. Journal of Clinical Oncology. 34: e22528-e22528. DOI: 10.1200/Jco.2016.34.15_Suppl.E22528 |
0.329 |
|
| 2016 |
Fruehauf JP, Farrokhian N, Sarkissian S, Kim J. Blockade of ARV7:HIF1α heterodimers after topotecan reverses enzalutamide resistance in 22Rv1 cells. Journal of Clinical Oncology. 34: e16594-e16594. DOI: 10.1200/Jco.2016.34.15_Suppl.E16594 |
0.309 |
|
| 2014 |
Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology. 74: 1279-89. PMID 25336084 DOI: 10.1007/S00280-014-2606-6 |
0.384 |
|
| 2014 |
Fruehauf JP, Alger B, Jakowatz JG, Hsiang D, Sender LS, Bettis C, Casey C. A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma. Journal of Clinical Oncology. 32: 9036-9036. DOI: 10.1200/Jco.2014.32.15_Suppl.9036 |
0.389 |
|
| 2013 |
Eroglu Z, Fruehauf JP. A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemotherapy and Pharmacology. 72: 263-7. PMID 23636451 DOI: 10.1007/S00280-013-2178-X |
0.4 |
|
| 2013 |
Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biology : Journal of the International Society For Matrix Biology. 32: 123-32. PMID 23202046 DOI: 10.1016/J.Matbio.2012.11.010 |
0.347 |
|
| 2013 |
Ein-Gal SY, Tsang W, Alger B, Parmakhtiar B, Jakowatz JG, Bettis C, Fruehauf J. Updated interim analysis of UCI 09-53: A phase II, single arm study of pazopanib and paclitaxel as first-line treatment for subjects with unresectable advanced melanoma. Journal of Clinical Oncology. 31: 9082-9082. DOI: 10.1200/Jco.2013.31.15_Suppl.9082 |
0.788 |
|
| 2012 |
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 126: 375-80. PMID 22683587 DOI: 10.1016/J.Ygyno.2012.06.002 |
0.316 |
|
| 2012 |
Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 34-41. PMID 22124101 DOI: 10.1200/Jco.2011.34.6270 |
0.447 |
|
| 2012 |
Fruehauf JP, Alger B, Parmakhtiar B, Jakowatz JG, Bettis C, Chuang T, Ein-Gal SY. A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: Interim analysis. Journal of Clinical Oncology. 30: 8524-8524. DOI: 10.1200/Jco.2012.30.15_Suppl.8524 |
0.751 |
|
| 2012 |
Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak VK. SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. Journal of Clinical Oncology. 30: 8521-8521. DOI: 10.1200/Jco.2012.30.15_Suppl.8521 |
0.38 |
|
| 2011 |
Fruehauf JP, Eroglu Z, Kong KM, Jakowatz JG, Akerley WL, Samlowski WE. A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8546. PMID 28021085 DOI: 10.1200/Jco.2011.29.15_Suppl.8546 |
0.391 |
|
| 2011 |
Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7462-9. PMID 21976544 DOI: 10.1158/1078-0432.Ccr-11-0534 |
0.401 |
|
| 2011 |
Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemotherapy and Pharmacology. 68: 1081-7. PMID 21769667 DOI: 10.1007/S00280-011-1703-Z |
0.391 |
|
| 2011 |
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3841-9. PMID 21531811 DOI: 10.1158/1078-0432.Ccr-10-2806 |
0.34 |
|
| 2011 |
Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia (New York, N.Y.). 13: 108-19. PMID 21403837 DOI: 10.1593/Neo.101092 |
0.773 |
|
| 2011 |
Fruehauf JP, Liau MC. Targeting epithelial-mesenchymal transition: Therapeutic reversal of the cancer stem cell phenotype Therapy. 8: 737-740. DOI: 10.2217/Thy.11.72 |
0.385 |
|
| 2011 |
Parmakhtiar B, Trapp V, Burger RA, Fruehauf JP. Abstract C208: Chemosensitization of ovarian cancer after topotecan modulation of HIF and p53. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C208 |
0.79 |
|
| 2011 |
Chase D, Sill M, Chambers M, Darcy K, Han E, Fruehauf J, Monk B, Buening B, Sorosky J, Burger R. Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial Gynecologic Oncology. 120: S65-S66. DOI: 10.1016/J.Ygyno.2010.12.157 |
0.386 |
|
| 2010 |
Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 13: 305-15. PMID 20927579 DOI: 10.1007/S10456-010-9187-8 |
0.75 |
|
| 2010 |
Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90. PMID 20870280 DOI: 10.1016/J.Ygyno.2010.08.016 |
0.784 |
|
| 2010 |
Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecologic Oncology. 119: 417-21. PMID 20846714 DOI: 10.1016/J.Ygyno.2010.08.010 |
0.312 |
|
| 2010 |
Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Molecular Cancer Therapeutics. 9: 2068-78. PMID 20606044 DOI: 10.1158/1535-7163.Mct-10-0201 |
0.421 |
|
| 2010 |
Willmott LJ, Fruehauf JP. Targeted therapy in ovarian cancer. Journal of Oncology. 2010: 740472. PMID 20130818 DOI: 10.1155/2010/740472 |
0.43 |
|
| 2010 |
Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 452-8. PMID 19913895 DOI: 10.1016/J.Ygyno.2009.10.062 |
0.328 |
|
| 2010 |
Fruehauf JP. Patient-specific tumor biology-based selection of ovarian cancer therapy Therapy. 7: 213-216. DOI: 10.2217/Thy.10.20 |
0.372 |
|
| 2010 |
Parmakhtiar B, Han E, Fruehauf JP. Abstract 3511: Modulation of HIF-1α by topotecan is related to topoisomerase I-associated with HIF-1α mRNA in ovarian cancer Cancer Research. 70: 3511-3511. DOI: 10.1158/1538-7445.Am10-3511 |
0.783 |
|
| 2010 |
Cao HST, Bouvet M, Romney E, Kaushal S, Keleman A, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MHG. Abstract 1686: Low dose metronomic gemcitabine has high antimetastatic efficacy in an orthotopic mouse model of pancreatic cancer Cancer Research. 70: 1686-1686. DOI: 10.1158/1538-7445.Am10-1686 |
0.368 |
|
| 2010 |
Willmott LJ, Monk B, Al-Ghazi M, Fruehauf J. Abstract 1399: The effect of radiation therapy with adjunctive oxaliplatin versus cisplatin chemotherapy in cervical cancer cell lines Cancer Research. 70: 1399-1399. DOI: 10.1158/1538-7445.Am10-1399 |
0.389 |
|
| 2009 |
Trapp V, Lee K, Doñate F, Mazar AP, Fruehauf JP. Redox-related antimelanoma activity of ATN-224. Melanoma Research. 19: 350-60. PMID 22760066 DOI: 10.1097/Cmr.0B013E32832C6324 |
0.706 |
|
| 2009 |
Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Research. 69: 4484-92. PMID 19366802 DOI: 10.1158/0008-5472.Can-08-3740 |
0.38 |
|
| 2009 |
Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 112: 583-9. PMID 19110305 DOI: 10.1016/J.Ygyno.2008.11.013 |
0.389 |
|
| 2008 |
Fruehauf JP, Lutzky J, McDermott DF, Brown CK, Pithavala YK, Bycott PW, Shalinsky D, Liau KF, Niethammer A, Rixe O. Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9006. PMID 27950791 DOI: 10.1200/Jco.2008.26.15_Suppl.9006 |
0.445 |
|
| 2008 |
Han ES, Burger R, Darcy KM, Sill MW, Greer BE, Sorosky JI, Fruehauf JP. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5577. PMID 27950426 DOI: 10.1200/Jco.2008.26.15_Suppl.5577 |
0.439 |
|
| 2008 |
Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Review of Anticancer Therapy. 8: 1751-7. PMID 18983235 DOI: 10.1586/14737140.8.11.1751 |
0.714 |
|
| 2008 |
Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Molecular and Cellular Biology. 28: 6496-509. PMID 18694961 DOI: 10.1128/Mcb.00477-08 |
0.707 |
|
| 2008 |
Mathews MS, Linskey ME, Hasso AN, Fruehauf JP. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surgical Neurology. 70: 649-52; discussion 6. PMID 18261776 DOI: 10.1016/J.Surneu.2007.06.029 |
0.337 |
|
| 2008 |
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Ricart AD, Olszanski AJ, Kim S, Spano J. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736) Journal of Clinical Oncology. 26: 3543-3543. DOI: 10.1200/Jco.2008.26.15_Suppl.3543 |
0.414 |
|
| 2007 |
Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 110: 2519-27. PMID 17932890 DOI: 10.1002/Cncr.23076 |
0.354 |
|
| 2007 |
Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 789-94. PMID 17289868 DOI: 10.1158/1078-0432.Ccr-06-2082 |
0.396 |
|
| 2007 |
Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation Oncogene. 26: 1188-1200. PMID 16936779 DOI: 10.1038/Sj.Onc.1209901 |
0.348 |
|
| 2007 |
Randall-Whitis L, Monk BJ, Han ES, Darcy K, Burger RA, Liao S, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in cervical cancer: A Gynecologic Oncology Group study Journal of Clinical Oncology. 25: 5536-5536. DOI: 10.1200/Jco.2007.25.18_Suppl.5536 |
0.408 |
|
| 2007 |
Han ES, Burger RA, Randall-Whitis L, Parmakhtiar B, Darcy K, Sill M, Connelly P, Monk BJ, Fruehauf JP. Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study Journal of Clinical Oncology. 25: 21021-21021. DOI: 10.1200/Jco.2007.25.18_Suppl.21021 |
0.785 |
|
| 2006 |
Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V. Mathematical modeling of cancer progression and response to chemotherapy. Expert Review of Anticancer Therapy. 6: 1361-76. PMID 17069522 DOI: 10.1586/14737140.6.10.1361 |
0.733 |
|
| 2006 |
Nguyen H, Tran A, Lipkin S, Fruehauf JP. Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Investigation. 24: 630-9. PMID 16982469 DOI: 10.1080/07357900600896281 |
0.344 |
|
| 2006 |
Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4523-32. PMID 16899598 DOI: 10.1158/1078-0432.Ccr-05-1830 |
0.332 |
|
| 2006 |
Cristini V, Frieboes H, Fruehauf J. Predictive computer simulations of tumor drug response demonstrate that 3-D hypoxic gradients significantly increase drug resistance Journal of Clinical Oncology. 24: 2071-2071. DOI: 10.1200/Jco.2006.24.18_Suppl.2071 |
0.379 |
|
| 2006 |
Fruehauf JP, Kong KM, Jakowatz JG. Phase II study of docetaxel and vinorelbine plus GM-CSF in malignant melanoma Journal of Clinical Oncology. 24: 18017-18017. DOI: 10.1200/Jco.2006.24.18_Suppl.18017 |
0.382 |
|
| 2006 |
Zhang M, Moore JC, Ko J, Fu W, Prabhu S, Fruehauf JP, Ong T. Increased eIF4E Expression and Phosphorylation in Late Phase Chronic Myelogenous Leukemia Occurs in a Bcr-Abl-Dependent Manner, and Can Be Targeted by a Novel Mnk Kinase Inhibitor, CGP57380, To Overcome Imatinib-Resistance. Blood. 108: 2193-2193. DOI: 10.1182/Blood.V108.11.2193.2193 |
0.34 |
|
| 2005 |
Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecologic Oncology. 98: 360-8. PMID 16000215 DOI: 10.1016/J.Ygyno.2005.04.036 |
0.356 |
|
| 2005 |
Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3733-42. PMID 15897570 DOI: 10.1158/1078-0432.Ccr-04-0056 |
0.397 |
|
| 2004 |
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Journal of Neuro-Oncology. 66: 365-75. PMID 15015670 DOI: 10.1023/B:Neon.0000014549.77646.F6 |
0.395 |
|
| 2004 |
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ. Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients International Journal of Gynecological Cancer. 14: 145-151. PMID 14764043 DOI: 10.1111/J.1048-891X.2004.014028.X |
0.341 |
|
| 2004 |
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecologic Oncology. 92: 160-6. PMID 14751152 DOI: 10.1016/J.Ygyno.2003.09.030 |
0.382 |
|
| 2004 |
Fruehauf JP, Buckmeier JA, Richardson M, Alberts DS. Dysregulation of angiogenesis promotes Melanoma progression: A Potential target for Chemoprevention. Pigment Cell Research. 17: 443-444. DOI: 10.1111/J.1600-0749.2004.00175_51.X |
0.324 |
|
| 2003 |
Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer. 98: 1658-63. PMID 14534882 DOI: 10.1002/Cncr.11714 |
0.397 |
|
| 2003 |
Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. Journal of Magnetic Resonance Imaging : Jmri. 18: 467-77. PMID 14508784 DOI: 10.1002/Jmri.10380 |
0.386 |
|
| 2003 |
Fruehauf JP, Alberts DS. Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 161: 126-45. PMID 12528805 DOI: 10.1007/978-3-642-19022-3_12 |
0.406 |
|
| 2002 |
Su MY, Yu H, Chiou JY, Wang J, Nalcioglu O, Fruehauf JP, Mehta RS, Baick CH. Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring. Technology in Cancer Research & Treatment. 1: 479-88. PMID 12625775 DOI: 10.1177/153303460200100608 |
0.392 |
|
| 2002 |
Monk BJ, Burger RA, Parker R, Radany EH, Redpath L, Fruehauf JP. Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecologic Oncology. 87: 193-9. PMID 12477451 DOI: 10.1006/Gyno.2002.6818 |
0.316 |
|
| 2002 |
Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecologic Oncology. 87: 8-16. PMID 12468336 DOI: 10.1006/Gyno.2002.6797 |
0.435 |
|
| 2002 |
Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP, Brem H. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. Journal of Neuro-Oncology. 58: 115-23. PMID 12164682 DOI: 10.1023/A:1016049111941 |
0.317 |
|
| 2002 |
Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP. Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Research and Treatment. 71: 95-102. PMID 11881914 DOI: 10.1023/A:1013843912560 |
0.379 |
|
| 2001 |
Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. Journal of Neuro-Oncology. 55: 195-204. PMID 11859975 DOI: 10.1023/A:1013845004294 |
0.35 |
|
| 2001 |
Mehta RS, Bornstein R, Yu IR, Parker RJ, McLaren CE, Nguyen KP, Li KT, Fruehauf JP. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Research and Treatment. 66: 225-37. PMID 11510694 DOI: 10.1023/A:1010604502627 |
0.382 |
|
| 2001 |
Meyskens FL, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma Pigment Cell Research. 14: 148-154. PMID 11434561 DOI: 10.1034/J.1600-0749.2001.140303.X |
0.31 |
|
| 2000 |
Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP. Biomarker conservation in primary and metastatic epithelial ovarian cancer Gynecologic Oncology. 78: 130-136. PMID 10926791 DOI: 10.1006/Gyno.2000.5837 |
0.395 |
|
| 1999 |
Moore MM, Tewari K, Rose GS, Fruehauf JP, Disaia PJ. Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient Gynecologic Oncology. 73: 452-454. PMID 10366478 DOI: 10.1006/Gyno.1999.5357 |
0.348 |
|
| 1998 |
Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TJ. Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. American Journal of Clinical Pathology. 110: 16-23. PMID 9661918 DOI: 10.1093/Ajcp/110.1.16 |
0.304 |
|
| 1998 |
Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma Cancer Detection and Prevention. 22: 185-194. PMID 9618039 DOI: 10.1046/J.1525-1500.1998.0Oa18.X |
0.337 |
|
| 1997 |
Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 10: 236-49. PMID 9263331 DOI: 10.1111/J.1600-0749.1997.Tb00490.X |
0.372 |
|
| 1996 |
Santin AD, Hiserodt JC, Fruehauf J, DiSaia PJ, Pecorelli S, Granger GA. Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecologic Oncology. 60: 468-74. PMID 8774659 DOI: 10.1006/Gyno.1996.0075 |
0.346 |
|
| 1996 |
Santin AD, Rose GS, Hiserodt JC, Fruehauf J, Eck LM, Garcia RI, Schranz V, Disaia PJ, Pecorelli S, Granger GA. Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers International Journal of Cancer. 65: 688-694. PMID 8598323 DOI: 10.1002/(Sici)1097-0215(19960301)65:5<688::Aid-Ijc21>3.0.Co;2-2 |
0.359 |
|
| 1994 |
Fruehauf JP, Manetta A. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression Contributions to Gynecology and Obstetrics. 19: 39-52. PMID 7995052 DOI: 10.1159/000423473 |
0.32 |
|
| Show low-probability matches. |